Meeder Asset Management Inc Arcus Biosciences, Inc. Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $418 - $541	-18 Reduced 60.0%	12 $0
Q2 2022 Aug 08, 2022	BUY	$17.23 - $37.73 $516 - $1,131	30 New	30 $1,000
Q3 2020 Nov 02, 2020	SELL	$17.14 - $25.47 $32,274 - $47,960	-1,883 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$13.97 - $36.56 $17,937 - $46,943	-1,284 Reduced 40.54%	1,883 $45,000
Q1 2020 May 15, 2020	BUY	$8.78 - $19.28 $16,734 - $36,747	1,906 Added 151.15%	3,167 $45,000
Q4 2019 Feb 13, 2020	SELL	$7.33 - $10.79 $26,959 - $39,685	-3,678 Reduced 74.47%	1,261 $13,000
Q3 2019 Oct 17, 2019	BUY	$6.44 - $10.18 $27,692 - $43,774	4,300 Added 672.93%	4,939 $46,000
Q2 2019 Aug 05, 2019	BUY	$7.29 - $13.38 $2,165 - $3,973	297 Added 86.84%	639 $5,000
Q1 2019 Apr 16, 2019	BUY	$8.95 - $12.49 $3,060 - $4,271	342 New	342 $4,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.